Rising Latin America Demand Will Expand Specialty Pharma Reach
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
CA$7.80
17.3% undervalued intrinsic discount15 Aug
CA$6.45
1Y
13.8%7D
2.4%